Skip to main content
. 2020 Aug 20;34:2058738420950851. doi: 10.1177/2058738420950851

Figure 1.

Figure 1.

Effects of benralizumab on SNOT-22, evaluated at baseline (before starting anti-IL-5Rα therapy), and 24 weeks after the first drug injection: individual values.